Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period.
Complete report is available @ http://www.rnrmarketresearch.com/systemic-psoriasis-therapeutics-in-major-developed-markets-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth-market-report.html .
